AIM
FBIO icon

Acrospire Investment Management’s Fortress Biotech FBIO Stock Holding History

Acrospire Investment Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-139
Closed -$10K – 502
2017
Q2 		$10K Buy
+139
New +$8.21K 0.01% 1794
2017
Q1 		– Sell
-36
Closed -$1K – 2286
2016
Q4 		$1K Sell
36
-240
-87% -$8.97K ﹤0.01% 2147
2016
Q3 		$12K Sell
276
-203
-42% -$8.63K 0.01% 1651
2016
Q2 		$19K Buy
+479
New +$22.3K 0.01% 1539

Other funds holding FBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CAM
ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return

Acrospire Investment Management's FBIO Position: Q3 2017 in Review

Acrospire Investment Management sold out of Fortress Biotech (FBIO) in Q3 2017, closing a stake of 139 shares — an estimated $10K sold.

Acrospire Investment Management first reported a position in FBIO in Q2 2016 and held it in 4 quarters. The position peaked at $19K in Q2 2016. 58 funds tracked by Wall St. Rank hold FBIO as of Q3 2017.

  • Acrospire Investment Management reported no remaining Fortress Biotech position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 139 Fortress Biotech shares in Q3 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in Fortress Biotech in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Fortress Biotech position peaked at $19K in Q2 2016.
  • 58 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.